Needham & Company LLC reaffirmed their hold rating on shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) in a research report sent to investors on Tuesday.

“Regulus reported 3Q17 financial results last wk and we met w/ mgmt for an update today. Both planned clinical trials of RG-012 in Alport Syndrome pts are now underway and an IND has been submitted for RGLS4326 in Autosomal Dominant Polycystic Kidney Disease. Mgmt has identified male X-linked Alport Syndrome as target pt population for clinical development going forward, due to rapid and homogeneous disease progression. We expect top-line results from 10- patient RG-012 biopsy trial early next yr and from 40-patient RG-012 HERA Phase 2 efficacy trial in early 2019. Maintain HOLD, awaiting more data from lead RG-012 program, but also note encouraging progression of platform/ pipeline behind it.”,” Needham & Company LLC’s analyst wrote.

Several other equities research analysts have also weighed in on the stock. Zacks Investment Research raised shares of Regulus Therapeutics from a hold rating to a buy rating and set a $1.50 target price on the stock in a report on Tuesday, October 10th. Wedbush reissued an ourperform rating and set a $4.00 price objective on shares of Regulus Therapeutics in a report on Monday, August 7th. Finally, Chardan Capital lowered shares of Regulus Therapeutics from a buy rating to a neutral rating in a report on Wednesday, August 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. Regulus Therapeutics presently has an average rating of Hold and a consensus target price of $2.60.

Regulus Therapeutics (RGLS) traded down $0.02 on Tuesday, hitting $0.92. 3,410,232 shares of the stock traded hands, compared to its average volume of 887,570. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.77 and a current ratio of 6.77. Regulus Therapeutics has a fifty-two week low of $0.79 and a fifty-two week high of $3.10.

COPYRIGHT VIOLATION WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/regulus-therapeutics-rgls-hold-rating-reaffirmed-at-needham-company-llc/1712273.html.

A number of large investors have recently modified their holdings of RGLS. Quantitative Investment Management LLC bought a new stake in Regulus Therapeutics during the 2nd quarter worth about $103,000. GSA Capital Partners LLP acquired a new position in Regulus Therapeutics during the 2nd quarter valued at about $139,000. LMR Partners LLP acquired a new position in Regulus Therapeutics during the 2nd quarter valued at about $164,000. Tudor Investment Corp ET AL lifted its position in Regulus Therapeutics by 131.5% during the 1st quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 61,373 shares during the period. Finally, Royal Bank of Canada lifted its position in Regulus Therapeutics by 12.1% during the 2nd quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock valued at $182,000 after purchasing an additional 19,934 shares during the period. 33.45% of the stock is currently owned by hedge funds and other institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.